¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ±Û¾²±â ¼öÁ¤ »èÁ¦

°æÈñ´ëÇб³º´¿ø °æÈñ½ÅÀ忬¼ö °­ÁÂ/ ´ëÇÑ ÀüÇØÁú ÇÐȸ Ãß°è Çмú´ëȸ : 2019-01-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
°æÈñ´ëÇб³º´¿ø °æÈñ½ÅÀ忬¼ö °­ÁÂ/ ´ëÇÑ ÀüÇØÁú ÇÐȸ Ãß°è Çмú´ëȸ : 2019-01-20
±³À°ÀÏÀÚ : 2019-01-20
±³À°Àå¼Ò : °æÈñ´ëÇб³ Á¾ÇÕ°­Àǵ¿ ÁöÇÏ 1Ãþ ´ë°­´ç  
±³À°ÁÖÁ¦ : °æÈñ½ÅÀ忬¼ö °­ÁÂ/ ´ëÇÑ ÀüÇØÁú ÇÐȸ Ãß°è Çмú´ëȸ
ÁÖÃÖ±â°ü : °æÈñ´ëÇб³º´¿ø
´ã´çÀÚ : Á¶¹Ì¿µ
¿¬¶ôó : 02-958-8199  
À̸ÞÀÏ : kmcim@naver.com      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 40,000¿ø      
ºñ°í »çÀüÁ¢¼ö½Ã 30000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 01-20 °­´ç 09:00~09:20 Biomarker and precision medicine in IgA nephropathy  Á¤°æȯ(°æÈñ´ë) 
±³À°½Ã°£ 01-20 °­´ç 09:20~09:40 Recent update of Pathology in IgA nephropathy  ¼ºÁö¿¬(°æÈñ´ë) 
±³À°½Ã°£ 01-20 °­´ç 09:40~10:00 Knowhow to manage the IgA nephropathy patients  ÀÓõ±Ô(°æÈñ´ë) 
±³À°½Ã°£ 01-20 °­´ç 10:30~10:50 How succefully manage the catheter dysfunction in HD patients?  È²Çö¼®(°æÈñ´ë) 
±³À°½Ã°£ 01-20 °­´ç 10:50~11:10 Paricalcitol, cinacalcet and etecalcetide: What is difference?  ±è¾ç±Õ(°æÈñ´ë) 
±³À°½Ã°£ 01-20 °­´ç 11:10~11:30 How to manage the failed graft after kidney transplantation?  ÀÌÅ¿ø(°æÈñ´ë) 
±³À°½Ã°£ 01-20 °­´ç 13:00~13:30 Dialysate Potassium, Dialysate Magnesium, and Hemodialysis Risk  ±èÈ¿»ó(¿ï»ê´ë) 
±³À°½Ã°£ 01-20 °­´ç 13:30~14:00 Ups and downs of dialysate calcium concentration in hemodialysis  ÀÌ»óÈ£(°æÈñ´ë) 
±³À°½Ã°£ 01-20 °­´ç 14:00~14:30 Automated blood pressure and CKD progression  À¯ÅÂÇö(¿¬¼¼´ë) 
±³À°½Ã°£ 01-20 °­´ç 14:30~15:00 Blood pressure targets for hemodialysis patients  ¹èÀºÈñ(Àü³²´ë) 
Åä·Ð 01-20 °­´ç 15:00~15:30 Panel discussion  ÀÌâȭ°í°­Áö±è¼¼Áß°­¼±¿ì(ÇѾç´ë°í·Á´ë¼­¿ï´ëÀÎÁ¦´ë) 
±³À°½Ã°£ 01-20 °­´ç 15:30~16:30 Interesting and educational cases  ·ùµ¿¿­¹ÚÁؼºÃÖ´ëÀº(ÀÌÈ­¿©´ëÇѾç´ëÃæ³²´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" °æÈñ´ëÇб³º´¿ø °æÈñ½ÅÀ忬¼ö °­ÁÂ/ ´ëÇÑ ÀüÇØÁú ÇÐȸ Ãß°è Çмú´ëȸ : 2019-01-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ±Û¾²±â ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼øõÇâ´ëÇб³ºÎõº´¿ø ±¸³»¿° ¹× ±¸°­³» º´º¯ : 2018-12-21
´ÙÀ½±Û ÀÎÁ¦´ëÇб³»ó°è¹éº´¿ø °³¿øÀÇ Áø·á¸¦ À§ÇÑ ¼Ò¾Æû¼Ò³â°ú ÁúȯÀÇ »õ·Î¿î Á¢±Ù°ú ÀÌÇØ : 2019-01-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20222 °æ±â ´ëÇÑÁ¤Çü¿Ü°úÀÇ»çȸ ¿ëÀÎÁö¿ª Çмú´ëȸ : 2024-04-28 0 17 2024-03-26
20221 ¼­¿ï (¿Â¶óÀÎ) Á¦9ȸ ºñ¸¸Àü¹®°¡ ±âÃÊ°úÁ¤ : 2024-04-28 0 17 2024-03-26
20220 ¼­¿ï 2024³â ´ëÇÑÇ׳ëÈ­ÇÐȸ Á¦23ȸ Ãá°èÇмú´ëȸ : 2024-04-28 0 12 2024-03-26
20219 Àü³² 2024³â Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°èÇмú´ëȸ : 2024-04-27 0 7 2024-03-26
20218 °­¿ø 2024³â ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ °­¿øÁöȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-04-27 0 8 2024-03-26
20217 °æ±â 2024³â ´ëÇѽºÆ÷Ã÷°úÇС¤¿îµ¿ÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-04-27 0 7 2024-03-26
20216 ¼­¿ï ´ëÇÑÁßȯÀÚÀÇÇÐȸ (¿Â¶óÀÎ) The 18th Basic Critical Care Review Course (BCCRC) : 2024-04-27 0 10 2024-03-26
20215 °æ±â ´ëÇѵΰæºÎ¿Ü°úÇÐȸ 2024 Ãá°è µÎ°æºÎ ÇÕµ¿¿¬¼öȸ : 2024-04-27 0 9 2024-03-26
20214 ¼­¿ï ´ëÇÑÁßȯÀÚÀÇÇÐȸ The 44th KSCCM Annual Congress ¡¤ Acute and Critical Care Conference 2024(2ÀÏÂ÷) : 2024-04-26 0 6 2024-03-26
20213 °æ±â °í·Á´ëÇб³¾È»êº´¿ø ¾È»ê ¹× ½ÃÈ­Áö¿ª À̺ñÀÎÈÄ°ú Àǻ縦 À§ÇÑ Áý´ãȸ(¸¸¼ººñºÎºñµ¿¿°) : 2024-04-26 0 4 2024-03-26
20212 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ¾È°ú ±Ý¿äÁý´ãȸ(Biomechanics in Glaucoma) : 2024-04-26 0 4 2024-03-26
20211 ºÎ»ê ´ëÇѾȰúÇÐȸ ºÎ»êÁöȸ Á¦ 509ȸ ÇмúÁý´ãȸ : 2024-04-25 0 7 2024-03-26
20210 ¼­¿ï ´ëÇÑÁßȯÀÚÀÇÇÐȸ The 44th KSCCM Annual Congress ¡¤ Acute and Critical Care Conference 2024(1ÀÏÂ÷) : 2024-04-25 0 8 2024-03-26
20209 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ÀÇ ¿¹¹æÁ¢Á¾ Àü·«°ú ³ëÇÏ¿ì: HPV ¹é½ÅÀ» Áß½ÉÀ¸·Î : 2024-04-25 0 10 2024-03-26
20208 ±¤ÁÖ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ Neuropsychiatry/û³âÁ¤½Å°Ç°­ : 2024-04-25 0 5 2024-03-26
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷